Pathophysiology of heparin-induced thrombocytopenia: Clinical and diagnostic implications - A review

Archives of Pathology and Laboratory Medicine

Volumn 124, Issue 11, 2000, Pages 1657-1666

  Fabris, F ^a   Ahmad, S ^a   Cella, G ^a   Jeske, W P ^a   Walenga, J M ^a   Fareed, J ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; SEROTONIN; THROMBIN INHIBITOR; THROMBOCYTE ANTIBODY; THROMBOCYTE FACTOR 4;

CELL ACTIVATION; CELL ADHESION; CLINICAL EXAMINATION; CLINICAL FEATURE; ENDOTHELIUM CELL; EPIDEMIOLOGICAL DATA; HUMAN; INCIDENCE; INFLAMMATION; LEUKOCYTE; PATHOPHYSIOLOGY; REVIEW; SEROTONIN RELEASE; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA;

HEPARIN; HUMANS; MODELS, BIOLOGICAL; THROMBOCYTOPENIA;

EID: 0033730964     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (122)

1. Effect of injected heparin on platelet levels in man
2. Biological aspects of heparin action: Heparin and platelet function
3. Normal and low molecular weight heparins: Interaction with human platelets
4. Heparin-associated thrombocytopenia
5. Heparin-induced thrombocytopenia
6. Heparin-induced thrombocytopenia: Toward consensus
7. Heparin-induced thrombocytopenia
8. A 14-year study of heparin-induced thrombocytopenia
9. Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with Orgaran (Org10172)
10. Heparin-associated thrombocytopenia: A critical review and pooled analysis
11. Heparin-induced thrombocytopenia
12. Thrombocytopenia found uncommonly during heparin therapy
13. Studies of the frequency of heparin-associated thrombo-cytopenia
14. Low incidence of thrombocytopenia during treatment with hog mucosa and beef lung heparin
15. Heparin-induced thrombocytopenia: A prospective study
16. Incidence of thrombocytopenia during therapy with bovine lung and porcine gut heparin preparations
17. Effect of low dose heparin on the platelet count
18. Heparin-associated thrombocytopenia: A prospective comparison of bovine lung heparin, manufactured by a new process, and porcine intestinal heparin
19. Thrombocytopenia occurring during the administration of heparin: A prospective study in 52 patients
20. Heparin-associated thrombocytopenia: A comparison of three heparin preparations
21. Thrombocytopenia induced by low-dose subcutaneous heparin
22. Heparin-associated thrombocytopenia: Low frequency in 104 patients treated with heparin of intestinal mucosal origin
23. Thrombocytes and treatment with heparin from porcine mucosa
24. Heparin-associated thrombocytopenia: A case report and prospective study
25. Heparin-induced thrombocytopenia: A case report and a prospective study
26. Heparin-associated thrombocytopenia: A prospective evaluation of 211 patients
27. Thrombocytopenia in a prospective, randomised, double-blind trial of bovine and porcine therapy
28. Heparin-induced thrombocytopenia: A prospective study
29. Heparin-induced thrombocytopenia: What is its real frequency?
30. Heparin-induced thrombocytopenia: A prospective study of 142 patients
31. Incidence of thrombocytopenia in medical patients on 'mini-dose' heparin prophylaxis
32. Heparin-induced thrombocytopenia: A clinicopathologic syndrome
33. Heparin-induced thrombocytopenia: Prevalence in a large cohort of patients and confirmed role of PF4-heparin complex as the main antigen for antibodies
34. Failure of early heparin cessation as treatment of heparin-induced thrombocytopenia
35. Heparin-induced thrombocytopenia and thrombosis: A prospective analysis of the incidence in patients with heart and cerebrovascular diseases
36. Thrombocytopenia due to a low molecular weight heparin during treatment with hypotensive and diuretics drugs
37. A fatal low molecular weight heparin-associated thrombocytopenia after hip surgery: Possible usefulness of PF4-heparin ELISA test
38. Heparin-induced thrombocytopenia in patients treated with low molecular weight or unfractionated heparin
39. Heparin-induced thrombocytopenia with thrombotic and hemorrhagic manifestation
40. Heparin immune thrombo-cytopenia: Evidence for a heparin-platelet complex as the antigenic determinant
41. Heparin-associated thrombocytopenia: The antibody is not heparin specific
42. Heparin-associated thrombocytopenia: Immune complexes are attached to the platelet membrane by the negative charge of highly sulphated oligosaccharides
43. Immuno-globulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4
44. Further evidence that alpha-granule components such as platelet factor 4 are involved in platelet-IgG-heparin interactions during heparin-associated thrombocytopenia
45. Heparin-associated thrombocytopenia: Antibody binding specificity to platelet antigens
46. Platelet factor 4 complexed to heparin is the target for antibodies in heparin-induced thrombocytopenia
47. The biological basis of immune heparin-induced thrombocytopenia
48. Heparin-associated thrombocytopenia: Isolation of the antibody and characterization of a multi-molecular PF4-heparin complex as the major antigen
49. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: A study of 44 cases
50. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells
51. Relative heparin-induced thrombocytopenic potential of low molecular weight heparins and new antithrombotic agents
52. Antigen generation in heparin-associated thrombocytopenia: The non-immunologic type and the immunologic type are closely linked in their pathogenesis
53. Heparin-induced thrombocytopenia syndrome (HIT): Diagnosis and treatment
54. Heparin-associated thrombocytopenia: Observations on the mechanism of platelet aggregation
55. The Fc receptor for immunoglobulin G (Fcγ Rlla) on human platelets
56. Heparin-induced thrombocytopenia: Laboratory studies
57. Heparin-induced thrombocytopenia: Mechanism of interaction of the heparin-dependent antibody with ptatelets
58. Single amino acid mutation of Fcγ receptor is associated with the development of heparin induced thrombocytopenia
59. FcψRlla His/Arg 131 polymorphism subclass-specific IgG anti-heparin/PF4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis
60. Simultaneous binding of heparin and platelet factor-4 to platelets: Further insights into mechanism of heparin-induced thrombocytopenia
61. Characterization of the humoral immune response in heparin-induced thrombocytopenia
62. Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or low-molecular weight heparin
63. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia
64. Heparin-induced thrombocytopenia: Molecular pathogenesis
65. Pathogenicity of human anti-platelet factor 4 (PF4)/heparin in vivo: Generation of mouse anti-PF4/heparin and induction of thrombocytopenia by heparin
66. Lack of thrombocytopenic response after low molecular weight heparins usage is due to the generation of non-functional anti-heparin-platelet factor 4 antibodies
67. Functional heterogeneity of anti-heparin-platelet factor 4 antibodies: Implications in the pathogenesis of the HIT syndrome
68. Soluble adhesion molecules in the HIT syndrome: Pathophysiologic role and therapeutic modulation
69. Antibody-mediated thrombosis
70. Pathophysiology of heparin-induced thrombocytopenia (HIT)
71. Heparin-induced thrombocytopenia and thrombosis: Clinical and laboratory studies
72. Warfarin and heparin-induced skin necrosis and the purple toe syndrome: Infrequent complications of anticoagulant treatment
73. Heparin-induced thrombocytopenia with thrombosis: Incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated in a single institution
74. Heparin-associated thrombosis despite normal platelet counts
75. Arterial embolism occurring during systemic heparin therapy
76. Orgaran (danaparoid sodium) use in the syndrome of heparin-induced thrombocytopenia
77. A diagnostic test for heparin-induced thrombocytopenia
78. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay
79. Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia
80. Laboratory diagnosis of heparin-induced thrombocytopenia
81. Laboratory tests for heparin-induced thrombocytopenia: A multicenter study
82. A rapid and sensitive test for diagnosing heparin-induced thrombocytopenia
83. Diagnostic tests in heparin-induced thrombocytopenia
84. A bioluminescent adenosine nucleotide release assay for the diagnosis of heparin-induced thrombocytopenia
85. A sensitive and specific functional flow cytometric assay for the diagnosis of heparin-induced thrombocytopenia
86. Effect of glycoprotein IIb/IIIa antagonists on the HIT serum-induced activation of platelets
87. Detection of drug-dependent, platelet-reactive antibodies by solid-phase red cell adherence assays
88. 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia
89. Heparin-induced platelet aggregation vs. platelet factor 4 enzyme-linked immunosorbent assay in the diagnosis of heparin-induced thrombocytopenia-thrombosis
90. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery
91. Laboratory tests for the diagnosis of heparin-induced thrombocytopenia
92. Management of heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome
93. Heparin-induced thrombocytopenia: What the serologists have taught us
94. Presence of autoantibodies to interleukin 8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia
95. Comparison of two PF4/ heparin ELISA assays for the laboratory diagnosis of heparin-induced thrombocytopenia
96. Comparison between platelet factor 4/ heparin complexes ELISA and platelet aggregation test in heparin-induced thrombocytopenia
97. Safety of warfarin anticoagulation on patients with heparin-induced thrombocytopenia
98. Platelet aggregation in response to four low molecular weight heparins and the heparinoid ORG10172 in patients with heparin-induced thrombocytopenia
99. Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia
100. Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome
101. Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia
102. Treatment of serious heparin induced thrombocytopenia by plasma exchange: Report of 4 cases
103. Correction of severe heparin-induced thrombocytopenia with intravenous immunoglobulin
104. Anticoagulation in patients with heparin-induced thrombocytopenia type II
105. Binding of platelet factor 4 to heparin oligosaccharides
106. Can low molecular weight heparins and heparinoids be safely given to patients with heparin-induced thrombocytopenia syndrome?
107. Heparin-induced thrombocytopenia: Clinical considerations of alternative anticoagulation with various glycosaminoglycans and thrombin inhibitors
108. Heparin-induced thrombocytopenia: Discrepancy between the presence of IgG cross-reacting in vitro with fraxiparine and its successful clinical use
109. Synthetic pentasaccharides do not cause platelet activation by anti-heparin-platelet factor 4 antibodies
110. Comment on 'Failure of Orgaran therapy in a patient with a previous heparin-induced thrombocytopenia syndrome'
111. Low molecular weight heparin(oid)s: Clinical investigation and practical recommendations
112. Failure of Orgaran therapy in a patient with a previous heparin-induced thrombocytopenia syndrome
113. Fatal danaparoid-sodium induced thrombocytopenia and arterial thromboses
114. Preliminary results of a prospective randomized controlled trial of argatroban vs. conventional therapy for heparin-induced thrombocytopenia
115. Use of argatroban during percutaneous coronary interventions in patients with heparin-induced thrombocytopenia
116. Recombinant hirudin (Lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study
117. Clinical applications of new antithrombotic agents
118. Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT
119. Inhibition of platelet activation in HIT: Thrombin inhibitors vs. antiplatelet agents
120. Treatment of heparin-induced thrombocytopenia
121. The glycoprotein IIb/IIIa antagonist c7E3 inhibits platelet aggregation in the presence of heparin-associated antibodies
122. Immunosuppression results in a reduction in anti-heparin-platelet factor 4 antibodies: Implications in the management of heparin-induced thrombocytopenia